The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated efficacy of mutant-selective PI3Ka inhibitor RLY-2608 in combination with fulvestrant in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial.
 
Sarah Sammons
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Foundation Medicine; Incyclix Bio; Loxo/Lilly; Novartis; Pfizer; Relay Therapeutics; Sermonix Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Lilly (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst)
 
Cristina Saura Manich
Honoraria - AstraZéneca; Daiichi Sankyo/Astra Zeneca; Eisai Europe,Ltd; Exeter Pharmaceuticals; Pfizer; Phillips Health Works; Pierre Fabre; Puma Biotechnology; Roche Pharma AG; Seagen; Solti; Zymeworks
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; F. Hoffmann LaRoche; Gilead Sciences; Lilly; MediTech; Menarini; Menarini; Novartis; Pfizer; Pharmalex; Philips Healthcare; Pierre Fabre; Pint Pharma; Puma Biotechnology; SeaGen; Synthon; Zymeworks
Speakers' Bureau - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exeter Pharmaceuticals; Lilly; Pfizer; Pierre Fabre; Puma Biotechnology; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (BMS) (Inst); CytomX Therapeutics (Inst); Daiichi Sakyo (Inst); Debiopharm Group (Inst); Genentech (Inst); GlaxoSmithKline (Inst); InnoUp (Inst); Janssen-Cilag SA (Inst); Lilly (Inst); Macrogenics (Inst); Menarini (Inst); Merck Health KGAA, Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Puma Biotechnology (Inst); Roche (Inst); Roche (Inst); Sanofi/Aventis (Inst); Seagen (Inst); SERVIER (Inst); Spanish Association Against Cancer Scientific Foundation and Cancer Research UK (Inst); Taiho Pharma USA Inc, (Inst)
Expert Testimony - AX`s consulting SARL; Boehringer Ingelheim; Bristol-Myers Squibb/Sanofi; Genentech; InnoUp; Merck Sharp and Dohme Spain; Novartis; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Daiichi Sankyo; Eisai Europe; Gilead Sciences; Lilly; Novartis; Pfizer; Pierre Fabre; Pierre Fabre; Puma Biotechnology; Roche; Seagen
 
Antoine Italiano
Honoraria - Bayer; Daiichi Sankyo; Epizyme; IPSEN; Lilly; Novartis; Roche
Consulting or Advisory Role - Bayer; Daiichi Sankyo; Epizyme; Immune Design; Lilly; Roche
Research Funding - AstraZeneca/MedImmune; Bayer; Merck Serono; Merck Serono; MSD Oncology; PharmaMar; Roche
Patents, Royalties, Other Intellectual Property - BMS
 
Alison Schram
Consulting or Advisory Role - Blueprint Medicines; Endeavor BioMedicines; Flagship Pioneering; Mersana; Merus NV; PMV Pharma; Redona Therapeutics; Relay Therapeutics; Repare Therapeutics; Schrodinger
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Black Diamond Therapeutics (Inst); Elevation Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Merus (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - PMV Pharma
 
Pablo Tolosa Ortega
Consulting or Advisory Role - Adamed; AstraZeneca; Daiichi Sankyo; Menarini; MSD Oncology; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; GlaxoSmithKline; Pfizer
 
Anne Schott
Research Funding - Arvinas (Inst); Celcuity (Inst); Genentech/Roche (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Contributor of 2 "cards" on breast cancer topics to UpToDate; Systems and Methods for Tissue Imaging, 8,185,186, Inventor, Submitted on 04/2008. This is a patent for use of diffusion MRI technology to quantitate response to neoadjuvant breast cancer therapy.
 
Angel Guerrero
Consulting or Advisory Role - AstraZeneca; Novartis
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Roche
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche
 
Santiago Ponce Aix
No Relationships to Disclose
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exact Sciences; GE Healthcare; Gilead Sciences; Guardant Health; Merck; Moderna Therapeutics; Novartis; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics
 
Kari Wisinski
Consulting or Advisory Role - ALX Oncology; Arvinas; AstraZeneca; Gilead Sciences; Loxo/Lilly; Pfizer; Stemline Therapeutics
Research Funding - Alterome Therapeutics (Inst); AstraZeneca (Inst); Context Therapeutics (Inst); Genentech (Inst); Novartis (Inst); Pfizer; Pfizer (Inst); Puma Biotechnology (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Zymeworks (Inst)
 
Jennifer Segar
No Relationships to Disclose
 
Mei Wei
Consulting or Advisory Role - Arvinas; AstraZeneca; bioTheranostics; Gilead Sciences; Merck; Novartis; Relay Therapeutics
Patents, Royalties, Other Intellectual Property - From Ambry Genetics for a software (I)
 
Jia Liu
Honoraria - MSD; Specialised Therapeutics
Consulting or Advisory Role - Greywolf Therapeutics (Inst); Starpharma (Inst); Taiho Pharmaceutical
Research Funding - Abbvie (Inst); ALX Oncology (Inst); AVEO (Inst); AVEO (Inst); Bayer (Inst); Bristol Ms Squibb (Inst); Bristol-Myers Squibb (Inst); Carina Biotech (Inst); Corvus Pharmaceuticals (Inst); Greywolf Therapeutics (Inst); IDEAYA Biosciences (Inst); ImmVirX (Inst); Innovent Biologics (Inst); Merus (Inst); MSD (Inst); Nested Therapeutics (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Starpharma (Inst)
Travel, Accommodations, Expenses - ImmVirX; Innovent Biologics; MSD; Starpharma
 
Alexander Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Julia McGuinness
Consulting or Advisory Role - AstraZeneca; Gilead Sciences
Speakers' Bureau - OncLive Clinical Congress Consultants; WebMD
Research Funding - GlaxoSmithKline (Inst); Greenwich Biosciences (Inst); HiberCell (Inst); Jazz Pharmaceuticals (Inst); Relay Therapeutics (Inst); Relay Therapeutics (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Cynthia Ma
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; Danatlas; Foundation Medicine; Genzyme; Lilly; Merck; Merck; Novartis; Olaris; Pfizer; Regor Therapeutics Group; Stemline Therapeutics; Stemline Therapeutics; Tersera; Tersera
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate: Authorship - served as a co-author on the subject of endocrine therapy for metastatic breast cancer and receive compensation as an author, less than a few hundred dollars a year. It does not affect my patient care or research.
 
Milana Bergamino Sirvén
Consulting or Advisory Role - AstraZeneca; Pfizer
Speakers' Bureau - AstraZeneca; Eisai; Novartis; Novartis
Patents, Royalties, Other Intellectual Property - Patent filled with the Institute of Cancer Research on the discrovery of new molecular subgroups in ER+/HER2+ Breast Cancer
 
Giuseppe Curigliano
Leadership - ESMO; ESMO; ESMO Open; European Society of Breast Cancer Specialists (EUSOMA=
Honoraria - Ellipses Pharma
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celcuity; Daichi-Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; GlaxoSmithKline; Guardant Health; Hengrui Therapeutics; Lilly; Menarini; Merck; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen; Veracyte
Speakers' Bureau - AstraZeneca; Daiichi Sankyo; Exact Sciences; Foundation Medicine; Gilead Sciences; Lilly; Menarini; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Daichii Sankyo; Pfizer; Roche/Genentech
 
Andreas Varkaris
Research Funding - OnKure; Relay Therapeutics